See more : Invincible Investment Corporation (8963.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Rad Laboratories, Inc. (BIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Rad Laboratories, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Skymark Airlines Inc. (9204.T) Income Statement Analysis – Financial Results
- NavInfo Co., Ltd. (002405.SZ) Income Statement Analysis – Financial Results
- The Macerich Company (MAC) Income Statement Analysis – Financial Results
- M8 Sustainable Limited (M8S.AX) Income Statement Analysis – Financial Results
- Geomega Resources Inc. (GOMRF) Income Statement Analysis – Financial Results
Bio-Rad Laboratories, Inc. (BIO)
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B | 2.02B | 2.18B | 2.13B | 2.07B | 2.07B | 1.93B | 1.78B | 1.76B | 1.46B | 1.27B | 1.18B | 1.09B | 1.00B | 892.72M | 817.51M | 725.88M | 549.50M | 441.90M | 426.90M | 418.80M | 396.60M | 355.30M | 328.60M | 330.30M | 310.70M | 286.70M | 236.30M | 198.90M | 159.50M | 126.60M | 102.30M |
| Cost of Revenue | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.75M | 930.09M | 897.77M | 996.53M | 954.22M | 908.19M | 895.64M | 835.63M | 784.40M | 801.84M | 669.69M | 561.39M | 534.50M | 479.94M | 437.99M | 383.24M | 356.33M | 300.06M | 227.70M | 181.50M | 169.90M | 164.10M | 155.20M | 139.00M | 134.40M | 124.30M | 122.20M | 113.30M | 95.30M | 81.50M | 63.50M | 52.70M | 45.60M |
| Gross Profit | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B | 1.12B | 1.18B | 1.18B | 1.16B | 1.18B | 1.09B | 999.84M | 962.52M | 791.36M | 712.54M | 646.49M | 610.07M | 565.39M | 509.49M | 461.18M | 425.83M | 321.80M | 260.40M | 257.00M | 254.70M | 241.40M | 216.30M | 194.20M | 206.00M | 188.50M | 173.40M | 141.00M | 117.40M | 96.00M | 73.90M | 56.70M |
| Gross Profit Ratio | 53.58% | 55.93% | 56.14% | 56.48% | 54.38% | 53.46% | 54.97% | 55.03% | 55.54% | 54.18% | 55.26% | 56.11% | 56.81% | 56.64% | 56.04% | 54.55% | 54.16% | 55.93% | 54.74% | 55.97% | 56.35% | 57.07% | 56.41% | 58.66% | 58.56% | 58.93% | 60.20% | 60.82% | 60.87% | 60.88% | 59.10% | 62.37% | 60.67% | 60.48% | 59.67% | 59.02% | 60.19% | 58.37% | 55.43% |
| Research & Development | 226.93M | 256.89M | 271.66M | 226.60M | 202.71M | 199.20M | 250.30M | 205.86M | 192.97M | 220.33M | 210.95M | 214.04M | 186.44M | 172.27M | 163.59M | 159.52M | 140.54M | 123.38M | 115.10M | 108.34M | 94.27M | 82.94M | 76.54M | 68.14M | 51.20M | 41.40M | 46.10M | 39.60M | 34.70M | 30.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 834.78M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 0.00 | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 820.62M | 827.83M | 879.57M | 800.27M | 824.63M | 833.29M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 635.21M | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Other Expenses | 0.00 | 44.57M | 26.78M | 24.49M | 26.09M | 36.59M | 12.20M | 14.85M | 11.08M | 13.01M | 12.77M | 21.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| Operating Expenses | 1.09B | 1.08B | 1.15B | 1.03B | 1.03B | 1.03B | 1.06B | 1.02B | 954.96M | 1.03B | 1.01B | 896.94M | 882.73M | 807.48M | 765.05M | 808.34M | 648.51M | 562.33M | 531.19M | 486.61M | 419.63M | 372.11M | 349.15M | 359.06M | 273.20M | 229.40M | 230.40M | 213.00M | 201.70M | 179.60M | 183.80M | 191.50M | 166.40M | 149.00M | 119.90M | 97.60M | 79.60M | 62.00M | 48.00M |
| Cost & Expenses | 2.29B | 2.32B | 2.43B | 2.13B | 2.08B | 2.10B | 2.03B | 1.95B | 1.85B | 2.03B | 1.96B | 1.81B | 1.78B | 1.64B | 1.55B | 1.61B | 1.32B | 1.12B | 1.07B | 966.55M | 857.62M | 755.35M | 705.48M | 659.12M | 500.90M | 410.90M | 400.30M | 377.10M | 356.90M | 318.60M | 318.20M | 315.80M | 288.60M | 262.30M | 215.20M | 179.10M | 143.10M | 114.70M | 93.60M |
| Interest Income | 100.90M | 58.00M | 18.90M | 18.20M | 30.50M | 26.60M | 19.10M | 14.70M | 10.10M | 13.50M | 13.40M | 11.40M | 8.20M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.44M | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M | 21.91M | 21.94M | 21.69M | 22.13M | 61.27M | 49.26M | 53.14M | 63.72M | 47.02M | 32.11M | 31.61M | 32.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 145.90M | 177.20M | 176.90M | 175.20M | 174.50M | 138.10M | 148.70M | 142.90M | 131.85M | 149.89M | 147.16M | 130.42M | 120.96M | 108.91M | 101.68M | 97.09M | 67.30M | 55.40M | 61.00M | 56.20M | 42.00M | 38.00M | 41.30M | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| EBITDA | -608.26M | -4.49B | 5.63B | 5.10B | 2.46B | 674.72M | 269.52M | 206.40M | 299.34M | 303.59M | 305.26M | 404.44M | 409.90M | 392.90M | 334.56M | 272.06M | 219.75M | 229.40M | 176.30M | 173.75M | 189.43M | 180.14M | 153.33M | 110.08M | 76.09M | 52.12M | 46.10M | 56.90M | 56.40M | 53.50M | 27.00M | 28.40M | 34.20M | 34.70M | 29.00M | 26.20M | 21.50M | 15.20M | 10.70M |
| EBITDA Ratio | -22.77% | 23.71% | 22.24% | 22.53% | 16.87% | 16.01% | 13.38% | 13.21% | 15.33% | 14.39% | 15.44% | 20.12% | 20.07% | 20.39% | 18.86% | 13.77% | 13.73% | 14.27% | 14.02% | 17.03% | 18.82% | 20.18% | 21.56% | 13.88% | 17.54% | 10.23% | 11.43% | 14.73% | 14.65% | 16.92% | 7.36% | 1.82% | 11.26% | 12.07% | 11.89% | 12.82% | 13.35% | 12.16% | 10.07% |
| Operating Income | 365.70M | 482.62M | 489.43M | 410.96M | 229.66M | -108.64M | 116.65M | 53.19M | 166.71M | 149.98M | 169.46M | 264.11M | 295.16M | 284.01M | 230.99M | 182.94M | 135.19M | 146.11M | 115.30M | 108.85M | 145.76M | 137.38M | 112.03M | 66.77M | 48.60M | 31.00M | 26.60M | 41.70M | 39.70M | 36.70M | 10.40M | 14.50M | 22.10M | 24.40M | 21.10M | 19.80M | 16.40M | 11.90M | 8.70M |
| Operating Income Ratio | 13.69% | 17.22% | 16.75% | 16.14% | 9.93% | -4.74% | 5.40% | 2.57% | 8.26% | 6.90% | 7.95% | 12.76% | 14.23% | 14.74% | 12.95% | 10.37% | 9.25% | 11.47% | 9.76% | 9.99% | 14.53% | 15.39% | 13.70% | 9.20% | 8.84% | 7.02% | 6.23% | 9.96% | 10.01% | 10.33% | 3.16% | 4.39% | 7.11% | 8.51% | 8.93% | 9.95% | 10.28% | 9.40% | 8.50% |
| Total Other Income/Expenses | -1.22B | -5.19B | 4.95B | 4.49B | 2.03B | 319.39M | -15.35M | -73.94M | -20.86M | -18.43M | -57.07M | -34.27M | -59.39M | -63.73M | -45.16M | -40.10M | -14.35M | -4.08M | -21.93M | -11.52M | -32.07M | -32.97M | -47.06M | -21.32M | -32.18M | 3.23M | -3.80M | -2.50M | -6.10M | -12.70M | -5.70M | 13.10M | -8.50M | -7.20M | -5.30M | -4.60M | -3.70M | -2.40M | -2.70M |
| Income Before Tax | -850.10M | -4.70B | 5.44B | 4.91B | 2.26B | 507.36M | 97.81M | 41.56M | 145.85M | 131.56M | 112.39M | 231.58M | 235.76M | 220.28M | 185.83M | 142.84M | 120.84M | 142.03M | 93.37M | 97.33M | 113.69M | 104.41M | 64.97M | 45.44M | 16.40M | 34.20M | 22.80M | 36.50M | 33.60M | 24.00M | 4.70M | 27.60M | 13.60M | 17.20M | 15.80M | 15.20M | 12.70M | 9.50M | 6.00M |
| Income Before Tax Ratio | -31.82% | -167.87% | 186.08% | 192.79% | 97.81% | 22.15% | 4.53% | 2.01% | 7.22% | 6.05% | 5.27% | 11.19% | 11.37% | 11.43% | 10.42% | 8.10% | 8.27% | 11.15% | 7.91% | 8.93% | 11.33% | 11.70% | 7.95% | 6.26% | 2.98% | 7.74% | 5.34% | 8.72% | 8.47% | 6.75% | 1.43% | 8.36% | 4.38% | 6.00% | 6.69% | 7.64% | 7.96% | 7.50% | 5.87% |
| Income Tax Expense | -212.78M | -1.08B | 1.19B | 1.10B | 502.41M | 146.36M | -16.94M | 13.44M | 32.75M | 42.71M | 34.57M | 62.28M | 57.74M | 33.35M | 36.67M | 44.58M | 26.55M | 38.76M | 15.79M | 31.04M | 37.52M | 36.54M | 20.79M | 13.63M | 4.70M | 9.90M | 6.40M | 9.10M | 8.40M | 8.40M | 1.90M | 12.00M | 5.40M | 6.50M | 5.70M | 5.70M | 5.00M | 3.40M | 1.70M |
| Net Income | -637.32M | -3.63B | 4.25B | 3.81B | 1.76B | 361.00M | 114.74M | 28.13M | 113.09M | 88.85M | 77.79M | 169.23M | 178.22M | 185.49M | 144.62M | 89.51M | 92.99M | 103.26M | 81.55M | 68.24M | 76.17M | 67.86M | 44.18M | 31.10M | 11.70M | 24.30M | 16.40M | 26.20M | 25.20M | 15.60M | 2.80M | 15.60M | 8.20M | 10.70M | 10.10M | 9.50M | 7.70M | 6.10M | 4.30M |
| Net Income Ratio | -23.86% | -129.45% | 145.57% | 149.83% | 76.08% | 15.76% | 5.31% | 1.36% | 5.60% | 4.08% | 3.65% | 8.18% | 8.60% | 9.63% | 8.11% | 5.07% | 6.36% | 8.11% | 6.91% | 6.26% | 7.59% | 7.60% | 5.40% | 4.28% | 2.13% | 5.50% | 3.84% | 6.26% | 6.35% | 4.39% | 0.85% | 4.72% | 2.64% | 3.73% | 4.27% | 4.78% | 4.83% | 4.82% | 4.20% |
| EPS | -21.82 | -121.79 | 142.61 | 127.86 | 58.93 | 12.10 | 4.12 | 0.88 | 3.74 | 3.08 | 2.72 | 5.85 | 6.39 | 6.70 | 5.28 | 3.30 | 3.48 | 3.92 | 3.13 | 2.65 | 3.00 | 2.70 | 1.79 | 1.27 | 0.49 | 0.99 | 0.67 | 1.07 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| EPS Diluted | -21.82 | -121.79 | 140.83 | 126.20 | 58.27 | 11.94 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 | 5.20 | 3.24 | 3.41 | 3.83 | 3.06 | 2.58 | 2.90 | 2.61 | 1.74 | 1.27 | 0.48 | 0.99 | 0.66 | 1.05 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| Weighted Avg Shares Out | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M | 29.84M | 29.66M | 29.44M | 29.19M | 28.88M | 28.59M | 28.29M | 28.03M | 27.67M | 27.40M | 27.11M | 26.72M | 26.38M | 26.06M | 25.72M | 25.42M | 25.13M | 24.65M | 24.42M | 24.22M | 24.53M | 24.66M | 24.60M | 24.41M | 24.23M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
| Weighted Avg Shares Out (Dil) | 29.21M | 29.79M | 30.21M | 30.16M | 30.18M | 30.23M | 30.03M | 29.65M | 29.41M | 29.13M | 28.91M | 28.64M | 28.47M | 28.15M | 27.83M | 27.64M | 27.29M | 26.95M | 26.66M | 26.49M | 26.31M | 26.00M | 25.44M | 24.57M | 24.33M | 24.72M | 24.85M | 24.95M | 24.41M | 24.26M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery Presentation to highlight Company's novel application of AI/machine learning capabilities...
Acasti Pharma to Attend BIO International Convention 2024
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal...
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
WALL, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced today that on May 22, 2024, it received a...
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a...
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 8:40 a.m. CDT. A...
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive...
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
Late clinical-stage company to provide update on Phase 3 treatment for celiac disease Late clinical-stage company to provide update on Phase 3 treatment for celiac disease
Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
BIO-key Expects to File Audited 2023 Results on Form 10-K and Report Q1 2024 Results and Host an Investor Call Next Week
HOLMDEL, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, today announced that it...
Source: https://incomestatements.info
Category: Stock Reports